UNSPSC 51111620: Acadesine

This classification denotes a purine antagonist with the molecular formula C9H14N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53IEF47846, chemically known as 1h-imidazole-4-carboxamide, 5-amino-1-beta-d-ribofuranosyl- but generally known as acadesine, which bears US NIH Compound Identifier 17513. Acadesine most often appears in base and phosphate form. European Medicines Agency schedules Acadesine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07365MIG.

UNSPSC 51111620 Acadesine, a Commodity code, represents pharmaceutical products procured by state health and human services agencies for pharmacy benefit programs and therapeutic initiatives. The code encompasses active pharmaceutical ingredients and finished drugs acquired through state procurement channels, including direct-to-manufacturer arrangements and benefit-manager intermediated purchasing. State and local issuing bodies under this code include health and human services departments managing Medicaid, employee health plans, and therapeutic pharmacy initiatives; the Texas Health and Human Services Commission represents a significant recent buyer pursuing innovative procurement models to manage pharmaceutical costs and improve prescription fulfillment efficiency.

The most recent activity concentrates in Texas, where the Health and Human Services Commission issued Request for Information No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, to solicit vendor capabilities regarding the implementation of a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. This RFI sought comprehensive information from potential vendors about establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside of existing arrangements with pharmacy benefit managers, group purchasing organizations, and wholesalers. The solicitation requested vendor experience with direct contracting for self-insured employers and health plans in both private and government sectors within the past two years, flexibility to negotiate contracts based on negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. As an exploratory information-gathering mechanism rather than a formal competitive solicitation, the RFI precedes a formal Request for Proposal with established financial and temporal parameters, signaling that Texas intends to develop detailed procurement specifications and implementation timelines for subsequent formal solicitations.